Financial Tear Sheet

Corporate Profile

LabCorp (NYSE: LH), an S&P 500 company, is a leading global life sciences company that is deeply integrated in guiding patient care, providing comprehensive clinical laboratory and end-to-end drug development services. With a mission to improve health and improve lives, LabCorp delivers world-class diagnostic solutions, brings innovative medicines to patients faster and uses technology to improve the delivery of care. LabCorp reported net revenues of over $10 billion in 2017. To learn more about LabCorp, visit www.labcorp.com, and to learn more about Covance Drug Development, visit www.covance.com.

More Information

Primary IR Contact
Scott Frommer
Vice President, Investor Relations
Laboratory Corporation of America Holdings
Phone: 336-436-5076
Fax: 336-436-1569
E-mail: investor@labcorp.com

Stock Performance
LH (Common)
ExchangeNYSE (US Dollar)
Price$170.77
Change (%) Stock is Up 0.91 (0.54%)
Volume332,863
52 Week Low$147.27
Market Cap$17,401,463,000
Rolling EPS12.61
PE Ratio13.5424
Shares Outstanding101,900,000
Data as of 10/15/18 3:10 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.
Stock chart for: LH.  Currently trading at $170.77 with a 52 week high of $190.35 and a 52 week low of $147.27.
Recent News & Events
10/10/18 - 5:30 p.m.
Walgreens and LabCorp to Open at Least 600 LabCorp at Walgreens Patient Service Centers
10/01/18 - 8:50 a.m.
Conversion Right Triggered For LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021
09/25/18 - 8:45 a.m.
LabCorp to Announce Third Quarter Financial Results on October 24, 2018
DateTitle
10/24/18 9:00 a.m. ET
Q3 2018 Laboratory Corporation of America Holdings Earnings Conference Call
Analyst Estimates / Ratings
Mean Recommendation: 2.0

Buy
SellStrong Buy
Unable to fulfill request.
SEC Filings
Filing DateForm
10/11/188-K XBRL SEC Filing Unavailable
10/01/188-K XBRL SEC Filing Unavailable
09/25/188-K XBRL SEC Filing Unavailable
09/24/188-K XBRL SEC Filing Unavailable
Corporate Governance
David P.  KingChairman and Chief Executive Officer
Glenn A. EisenbergExecutive Vice President and Chief Financial Officer
Gary M. HuffChief Executive Officer, LabCorp Diagnostics
John D.  RatliffChief Executive Officer, Covance Drug Development
Lance V. BerberianSenior Vice President and Chief Information Officer
Edward T. DodsonSenior Vice President and Chief Accounting Officer
F. Samuel Eberts IIISenior Vice President, Chief Legal Officer and Secretary
Lisa J. UthgenanntChief Human Resources Officer
Brian J. CaveneyChief Medical Officer
Ownership Summary
Shareholders
 HoldersValue ($MM)% O/SShares
Institution1,08217,603.9596.698,423,463
Mutual Fund1,5918,677.1649.350,221,767
Insider *1768.830.4393,249
*Insider values reflect direct beneficial ownership.
Top Holders
 Shares Held% O/SShare ChangeFiling Date
The Vanguard Group, Inc.10,737,88210.543,40806/30/18
Boston Partners5,667,8925.6-5,87506/30/18
BlackRock Institutional Trust Company, N.A.5,527,3315.4-288,22906/30/18
State Street Global Advisors (US)4,050,4794.0-84,38006/30/18
Nordea Funds Oy2,052,1102.0-118,35406/30/18
Amundi Pioneer Asset Management, Inc.1,905,8641.91,201,14106/30/18
Iridian Asset Management LLC1,758,9081.767,98706/30/18
OppenheimerFunds, Inc.1,700,7761.7903,55406/30/18
Dimensional Fund Advisors, L.P.1,425,3081.4-1,60506/30/18
JP Morgan Asset Management1,294,1231.3-5,65106/30/18